Abstract
Plasma membrane transporter proteins play an important role in taking up nutrients into and effluxing xenobiotics out of cells to sustain cell survival. In the last decade, a number of studies have shown that these physiologically important transporters affect absorption, distribution, and excretion of major anticancer agents in clinical use. More importantly, many transporters have been reported to be differentially upregulated in cancer cells compared to normal tissues, suggesting that the differential expression of transporters in cancer cells may become good targets for enhancing drug delivery as well as diagnostic markers for cancer therapy. Hence, utilizing the knowledge of transporter functions likely provides us with the possibility of delivering a drug to the target tissues, avoiding distribution to other tissues, and improving oral bioavailability. This chapter focuses on methodology to analyze the activity of transporters that are involved in drug transport.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Nakanishi, T., Tamai, I., Sai, Y., Sasaki, T., and Tsuji, A. (1997) Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080, Cancer Res. 57, 4118–4122.
Nakanishi, T., Tamai, I., Takaki, A., and Tsuji, A. (2000) Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int. J. Cancer 88, 274–280.
Gonzalez, D.E., Covitz, K.-M.Y., Sadee, W., and Mrsny, R.J. (1998) An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res. 58, 519–525.
Mitsuoka, K., Miyoshi, S., Kato, Y., Murakami, Y., Utsumi, R., Kubo, Y., Noda, A., Nakamura, Y., Nishimura, S., and Tsuji, A. (2008) Cancer detection using a pet tracer, 11c-glycylsarcosine, targeted to h+/peptide transporter. J. Nucl. Med. 49, 615–622.
Nakanishi, T. (2007) Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 4, 241–254.
Doyle, L.A., Yang, W., Abruzzo, L.V., Krogmann, T., Gao, Y., Rishi, A.K., and Ross, D.D. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U S A 95, 15665–15670.
Ross, D.D. (2000) Novel mechanisms of drug resistance in leukemia. Leukemia 14, 467–473.
Nakanishi, T., Doyle, L.A., Hassel, B., Wei, Y., Bauer, K.S., Wu, S., Pumplin, D.W., Fang, H.-B., and Ross, D.D. (2003) Functional characterization of human breast cancer resistance protein (BCRP, ABCG2) Expressed in the Oocytes of Xenopus laevis. Mol. Pharmacol. 64, 1452–1462.
Yanagida, O., Kanai, Y., Chairoungdua, A., Kim, D.K., Segawa, H., Nii, T., Cha, S.H., Matsuo, H., Fukushima, J.-i., Fukasawa, Y., Tani, Y., Taketani, Y., Uchino, H., Kim, J.Y., Inatomi, J., Okayasu, I., Miyamoto, K.-i., Takeda, E., Goya, T., and Endou, H. (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochimica et Biophysica Acta. 1514, 291–302.
Wolf, D.A., Wang, S., Panzica, M.A., Bassily, N.H., and Thompson, N.L. (1996) Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to schistosoma mansoni amino acid permease and caenorhabditis elegans gene products. Cancer Res. 56, 5012–5022.
Nawashiro, H., Otani, N., Shinomiya, N., Fukui, S., Ooigawa, H., Shima, K., Matsuo, H., Kanai, Y., and Endou, H. (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int. J. Cancer 119, 484–492.
Kim, D.K., Kanai, Y., Choi, H.W., Tangtrongsup, S., Chairoungdua, A., Babu, E., Tachama, K., Anzai, N., Iribe, Y., and Endou, H. (2002) Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells BBA Biomembrane 1565, 112–122.
Kanai, Y., Segawa, H., Miyamoto, K.-i., Uchino, H., Takeda, E., and Endou, H. (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 273, 23629–23632.
Bode, B.P., Fuchs, B.C., Hurley, B.P., Conroy, J.L., Suetterlin, J.E., Tanabe, K.K., Rhoads, D.B., Abcouwer, S.F., and Souba, W.W. (2002) Molecular and functional analysis of glutamine uptake in human hepatoma and liver-derived cells. Am. J. Physiol. Gastrointest. Liver Physiol. 283, G1062–1073.
Gupta, N., Miyauchi, S., Martindale, R.G., Herdman, A.V., Podolsky, R., Miyake, K., Mager, S., Prasad, P.D., Ganapathy, M.E., and Ganapathy, V. (2005) Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humans. Biochimica et Biophysica Acta (BBA). Mol. Basis Dis. 1741, 215–223.
Gupta, N., Prasad, P.D., Ghamande, S., Moore-Martin, P., Herdman, A.V., Martindale, R.G., Podolsky, R., Mager, S., Ganapathy, M.E., and Ganapathy, V. (2006) Up-regulation of the amino acid transporter ATB0,+ (SLC6A14) in carcinoma of the cervix. Gynecologic Oncology 100, 8–13.
Nakanishi, T., Hatanaka, T., Huang, W., Prasad, P.D., Leibach, F.H., Ganapathy, M.E., and Ganapathy, V. (2001) Na+- and Cl–-coupled active transport of carnitine by the amino acid transporter ATB0,+ from mouse colon expressed in HRPE cells and Xenopus oocytes. J. Physiol. (Lond) 532, 297–304.
Hatanaka, T., Huang, W., Nakanishi, T., Bridges, C.C., Smith, S.B., Prasad, P.D., Ganapathy, M.E., and Ganapathy, V. (2002) Transport of -Serine via the Amino Acid Transporter ATB0,+ Expressed in the Colon. Biochem. Biophys. Res. Comm. 291, 291–295.
Hatanaka, T., Nakanishi, T., Huang, W., Leibach, F.H., Prasad, P.D., Ganapathy, V., and Ganapathy, M.E. (2001) Na+- and Cl–-coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B0,+. J. Clin. Invest. 107, 1035–1043.
Huang, Y., Dai, Z., Barbacioru, C., and Sadee, W. (2005) Cystine-Glutamate Transporter SLC7A11 in Cancer Chemosensitivity and Chemoresistance. Cancer Res. 65, 7446–7454.
Zhang, S., Lovejoy, K.S., Shima, J.E., Lagpacan, L.L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J.W., Chen, X., Lippard, S.J., and Giacomini, K.M. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66, 8847–8857.
White, D.L., Saunders, V.A., Dang, P., Engler, J., Zannettino, A.C. W., Cambareri, A.C., Quinn, S.R., Manley, P.W., and Hughes, T.P. (2006) OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108, 697–704.
Okabe, M., Unno, M., Harigae, H., Kaku, M., Okitsu, Y., Sasaki, T., Mizoi, T., Shiiba, K., Takanaga, H., Terasaki, T., Matsuno, S., Sasaki, I., Ito, S., and Abe, T. (2005) Characterization of the organic cation transporter SLC22A16: A doxorubicin importer. Biochem. Biophys. Res. Comm. 333, 754–762.
Farr, X., Guillen-Gomez, E., Sanchez, L., Hardisson, D., Plaza, Y., Lloberas, J., Casado, F.J., Palacios, J., and Pastor-Anglada, M. (2004) Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int. J. Cancer 112, 959–966.
Spratlin, J., Sangha, R., Glubrecht, D., Dabbagh, L., Young, J.D., Dumontet, C., Cass, C., Lai, R., and Mackey, J.R. (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin. Cancer Res. 10, 6956–6961.
Koukourakis, M.I., Giatromanolaki, A., Harris, A.L., and Sivridis, E. (2006) Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 66, 632–637.
Fang, J., Quinones, Q.J., Holman, T.L., Morowitz, M.J., Wang, Q., Zhao, H., Sivo, F., Maris, J.M., and Wahl, M.L. (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol. Pharmacol. 70, 2108–2115.
Nabulsi, N.B., Smith, D.E., and Kilbourn, M.R. (2005) [11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice. Bioorg. Med. Chem. 13, 2993–3001.
Yamaoka, K., Tanigawara, Y., Nakagawa, T., and Uno, T. (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobiodyn. 4, 879–885.
Doyle, L.A., and Ross, D.D. (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340–7358.
Ambudkar, S.V., Kimchi-Sarfaty, C., Sauna, Z.E., and Gottesman, M.M. (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468–7485.
Deeley, R., Westlake, C., and Cole, S. (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86, 849–899.
Acknowledgements
We thank Dr. Akira Tsuji (at Kanazawa University, Japan) for his permission to use the data shown as Fig. 5.2 and Dr. Ikumi Tamai (at Kanazawa University, Japan) for his thoughtful suggestions in describing this chapter.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Nakanishi, T., Ross, D.D., Mitsuoka, K. (2010). Methods to Evaluate Transporter Activity in Cancer. In: Yan, Q. (eds) Membrane Transporters in Drug Discovery and Development. Methods in Molecular Biology, vol 637. Humana Press. https://doi.org/10.1007/978-1-60761-700-6_5
Download citation
DOI: https://doi.org/10.1007/978-1-60761-700-6_5
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-699-3
Online ISBN: 978-1-60761-700-6
eBook Packages: Springer Protocols